Epilepsy Trial, Recruiting NCT05223985 Sponsor: Alcis Condition: Epilepsy
Back to Epilepsy

Epilepsy Trial, Recruiting

NCT05223985
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 months to 65 years
  • People who have epilepsy that focuses in one area of the brain, does not respond well to medication, and significantly affects daily life
  • People (or their parent or guardian, for minors) who are informed about the study and willing to sign a consent form approved by an ethics committee — if one parent is unavailable within the required timeframe, one parent's signature may be accepted
  • People who are covered by French social security or an equivalent recognised scheme
  • For new participants joining going forward: people being considered for a brain monitoring procedure called SEEG as part of an assessment to see whether epilepsy surgery may help
  • For participants being included based on past and future data: people who have already had a SEEG procedure using a specific device (ALCIS) before the study's start visit, who have had at least 12 months of follow-up visits planned going forward, and for whom complete records are available from all previous visits (confirm with trial site)

Who may not be able to join:

  • People who, in the assessor's judgement, would not be able to follow the study procedures — for example, difficulty understanding study questions or being unable to attend scheduled appointments
  • People with any medical condition that the investigator believes could affect the study, such as relevant allergies (confirm with trial site)
  • People who are pregnant, as the SEEG procedure is not considered safe during pregnancy
  • Adults who are under a legal protection order (for example, under guardianship)
  • People whose skull thickness measures less than 2 mm

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33 (0)3 81 61 54 16

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Alcis
Registry
ClinicalTrials.gov
Start date
29 April 2022
Est. completion
30 December 2024

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Signal quality; Modification of Electroencephalography trace post-coagulation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov